Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02780011
Title Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Acronym AD3LE
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors The Methodist Hospital System
Age Groups: adult
Covered Countries USA

No variant requirements are available.